ArticleScientific reports2025
Platelet-rich plasma and IL-1β antagonist receptor peptide attenuate the inflammatory process of muscle injury in wistar rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Elastic Compression Attenuates Inflammatory Response in a Model of Acute Subcutaneous Abdominal Inflammation.Aesthetic plastic surgery · 2026Article
- Adenosine 5'-monophosphate prevents sepsis-associated muscle wasting by activating AMPK and suppressing IL-1β inflammatory cytokines.Journal of intensive care · 2026Article
- Potential Influence of Myokines on Skeletal Muscle Tissue Hypertrophy Signaling Pathways: A Narrative Review.Biomolecules · 2026Review
- Peptide-based targeted drug delivery strategies for osteoarthritis treatment.npj biomedical innovations · 2026Review
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle injuries are frequent in sports, necessitating therapies that reduce inflammation and enhance repair. Platelet-rich plasma (PRP), derived from autologous blood, offers high concentrations of platelets and growth factors for tissue regeneration. Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, is crucial in inflammation, and its inhibition may speed up healing, but the high cost of blockers limits their use. This study evaluated the effects of leukocyte-rich PRP (LR-PRP), leukocyte-poor PRP (LP-PRP), and the peptide antagonist DAP1-2 on inflammation after muscle injury. Eighty-four rats were divided into seven groups: Control; muscle injury (MI); MI + LR-PRP; MI + LP-PRP; MI + DAP1-2; MI + LR-PRP + DAP1-2; MI + LP-PRP + DAP1-2. Muscle damage was induced via contusion of the right gastrocnemius, with treatments administered 24 h post-injury. On day five, groups were euthanized for analysis. RT-qPCR measured NF-kB and IL-1β expression, while ELISA assessed pro- and anti-inflammatory cytokines, including TNF-α and IL-6. All treated groups showed reduced inflammatory and oxidative stress markers by day five, with the PRP-LP + DAP1-2 group showing the most significant effects, indicating enhanced tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.